Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

Table 2 Summary of tumour responses during the study period for the ITT population*

Tumour response, n (%)	Cisplatin + gemcitabine + axitinib, (n = 38)
Complete response	1 (2.6)
Partial response	14 (36.8)
Stable disease	9 (23.7)
Progressive disease	3 (7.9)
Indeterminate response^†	8 (21.1)
Not assessed due to early death^‡	2 (5.3)
Baseline status uncertain^§	1 (2.6)
Objective response (complete + partial)	15 (39.5)

ITT = intent-to-treat.
*Study period comprised the treatment period plus 28-day follow-up period after the last dose of study drug.
^†Imaging scans unavailable or performed >28 days after the last study dose.
^‡Death occurring before the first scheduled tumour assessment.
^§No baseline assessment performed.

ISSN: 1471-2407